STOCK TITAN
  1. Home
  2. News
  3. BSX

Boston Scientific Corp. - BSX STOCK NEWS

Welcome to our dedicated news page for Boston Scientific (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Boston Scientific's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Boston Scientific's position in the market.

News
Boston Scientific: Sparking Social Change Through Volunteering
Rhea-AI Summary
Boston Scientific's Social Change Champions program aims to provide leadership opportunities for employees while making a sustainable impact in the health equity space. The company's recent pilot program involved 12 employees traveling to Lima, Peru, to help Socios en Salud, a recent Signature Health Grant recipient, with challenges such as defining a growth strategy and providing crucial HPV testing for cervical cancer. The program resulted in action plans to eliminate inefficiencies and boost revenue, as well as the creation of FAQs to educate women on the importance of cervical cancer screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
News
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) reported strong financial results for the fourth quarter and full year 2023, with net sales of $3.725 billion and $14.240 billion, respectively. The company achieved significant growth in net sales, GAAP net income, and adjusted EPS compared to the prior year period. The CEO, Mike Mahoney, expressed gratitude towards the global team for the exceptional results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
earnings
-
News
Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System, a new treatment for paroxysmal atrial fibrillation. The system uses non-thermal electric fields to ablate heart tissue, with positive clinical trial data and real-world use supporting its safety and efficacy. The system has also received Breakthrough Device Designation and CE Mark, with plans for immediate launch in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
fda approval
News
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
Rhea-AI Summary
Axonics, Inc. (AXNX) Reports Strong Revenue Growth in Q4 and FY23, Expects 27% and 34% Increases Respectively. Preliminary unaudited revenue for Q4 2023 is $109.3 to $109.7 million, an increase of 27% compared to the prior year period. Fiscal Year 2023 revenue is expected to be approximately $366.1 million, an increase of 34% compared to fiscal year 2022. The company attributes the growth to higher utilization and share of wallet at existing customers and the onboarding of new accounts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
earnings
-
News
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
Rhea-AI Summary
Axonics, Inc. (AXNX) has entered into a definitive agreement to be acquired by Boston Scientific Corporation (BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion. Axonics brings a complementary product portfolio to the Boston Scientific Urology business and has pioneered significant enhancements to sacral neuromodulation therapy for bladder and bowel dysfunction and urethral bulking for women with stress urinary incontinence. The transaction is expected to close in the first half of 2024, pending approval of Axonics’ stockholders and receipt of required regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
acquisition
-
News
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
Rhea-AI Summary
Boston Scientific Corporation (BSX) to acquire Axonics, Inc. (AXNX) for $3.7 billion, expanding its urology portfolio with technologies to treat urinary and bowel dysfunction. Axonics' products include the Axonics R20TM and the Axonics F15TM Systems for sacral neuromodulation therapy, with expected high revenue growth in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
acquisition
News
Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
Rhea-AI Summary
Boston Scientific Corporation (BSX) to host conference call on January 31, 2024, to discuss Q4 financial results and business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
earnings
-
News
Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System as a first-line treatment for persistent atrial fibrillation (AF). The trial aims to compare the outcomes of ablation with the FARAPULSE PFA System to anti-arrhythmic drug therapy commonly prescribed for patients with persistent AF. The company anticipates FDA approval of the system in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
clinical trial
-
News
NACD New England honors Waters Corp. and Devoted Health as Public and Private Company “Boards of the Year”
Rhea-AI Summary
NACDNE Honors David Roux, Waters Corp (NYSE: WAT), and Devoted Health; Roux Receives Lifetime Achievement Award Named for R. Robert Popeo
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
News
Boston Scientific: When a Loved One Has Parkinson’s Disease
Rhea-AI Summary
Boston Scientific (BSX) Announces Positive Impact of Treatment on Parkinson's Disease Patient
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
Stock BSX logo
Boston Scientific Corp.

NYSE:BSX

BSX Rankings

#124 Ranked by Market Cap
#1082 Ranked by Stock Gains
N/A Ranked by Dividends

BSX Stock Data

100.06B
1.46B
0.19%
93.66%
0.85%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Marlborough

About BSX

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.